53 research outputs found

    Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children

    Get PDF
    SummaryObjectiveTo examine the risk factors of carbapenem non-susceptibility and mortality among children with Acinetobacter baumannii bacteremia.MethodsA retrospective chart review was conducted of 180 cases with A. baumannii bacteremia.ResultsThe 30-day mortality risk of A. baumannii bacteremia was 26.1%. Carbapenem-non-susceptible A. baumannii was identified in 51.7% of cases. Logistic regression analysis indicated that prematurity, use of mechanical ventilation, and prior exposure to carbapenem antibiotics were independently associated with carbapenem-non-susceptible A. baumannii bacteremia, with adjusted odds ratios (aORs) and 95% confidence intervals (CIs) of 3.36 (1.17–9.65), 5.59 (2.24–13.97), and 2.97 (1.01–8.77), respectively. Further, carbapenem non-susceptibility, cancer-related neutropenia, organ dysfunction, admission to the intensive care unit, catheter-related bacteremia, and treatment with sulbactam-containing regimens were associated with mortality with aORs and 95% CIs of 4.76 (1.58–14.32), 4.54 (1.09–18.79), 25.95 (5.13–131.33), 3.53 (1.29–9.71), 0.25 (0.084–0.72), and 0.14 (0.046–0.45), respectively.ConclusionsThe majority of A. baumannii bacteremia was caused by carbapenem-non-susceptible strains with a high mortality rate. Carbapenem non-susceptibility, cancer-related neutropenia, the presence of organ dysfunction, and admission to an intensive care unit were associated with an increased mortality risk, whereas catheter-related bacteremia and treatment with a sulbactam-containing regimen were associated with decreased mortality among children with A. baumannii bacteremia

    Reconstructing unseen transmission events to infer dengue dynamics from viral sequences.

    Get PDF
    For most pathogens, transmission is driven by interactions between the behaviours of infectious individuals, the behaviours of the wider population, the local environment, and immunity. Phylogeographic approaches are currently unable to disentangle the relative effects of these competing factors. We develop a spatiotemporally structured phylogenetic framework that addresses these limitations by considering individual transmission events, reconstructed across spatial scales. We apply it to geocoded dengue virus sequences from Thailand (N = 726 over 18 years). We find infected individuals spend 96% of their time in their home community compared to 76% for the susceptible population (mainly children) and 42% for adults. Dynamic pockets of local immunity make transmission more likely in places with high heterotypic immunity and less likely where high homotypic immunity exists. Age-dependent mixing of individuals and vector distributions are not important in determining spread. This approach provides previously unknown insights into one of the most complex disease systems known and will be applicable to other pathogens

    Standardized Interpretation of Chest Radiographs in Cases of Pediatric Pneumonia From the PERCH Study.

    Get PDF
    BACKGROUND.: Chest radiographs (CXRs) are a valuable diagnostic tool in epidemiologic studies of pneumonia. The World Health Organization (WHO) methodology for the interpretation of pediatric CXRs has not been evaluated beyond its intended application as an endpoint measure for bacterial vaccine trials. METHODS.: The Pneumonia Etiology Research for Child Health (PERCH) study enrolled children aged 1-59 months hospitalized with WHO-defined severe and very severe pneumonia from 7 low- and middle-income countries. An interpretation process categorized each CXR into 1 of 5 conclusions: consolidation, other infiltrate, both consolidation and other infiltrate, normal, or uninterpretable. Two members of a 14-person reading panel, who had undertaken training and standardization in CXR interpretation, interpreted each CXR. Two members of an arbitration panel provided additional independent reviews of CXRs with discordant interpretations at the primary reading, blinded to previous reports. Further discordance was resolved with consensus discussion. RESULTS.: A total of 4172 CXRs were obtained from 4232 cases. Observed agreement for detecting consolidation (with or without other infiltrate) between primary readers was 78% (κ = 0.50) and between arbitrators was 84% (κ = 0.61); agreement for primary readers and arbitrators across 5 conclusion categories was 43.5% (κ = 0.25) and 48.5% (κ = 0.32), respectively. Disagreement was most frequent between conclusions of other infiltrate and normal for both the reading panel and the arbitration panel (32% and 30% of discordant CXRs, respectively). CONCLUSIONS.: Agreement was similar to that of previous evaluations using the WHO methodology for detecting consolidation, but poor for other infiltrates despite attempts at a rigorous standardization process

    Global respiratory syncytial virus–related infant community deaths

    Get PDF
    Background Respiratory syncytial virus (RSV) is a leading cause of pediatric death, with >99% of mortality occurring in low- and lower middle-income countries. At least half of RSV-related deaths are estimated to occur in the community, but clinical characteristics of this group of children remain poorly characterized. Methods The RSV Global Online Mortality Database (RSV GOLD), a global registry of under-5 children who have died with RSV-related illness, describes clinical characteristics of children dying of RSV through global data sharing. RSV GOLD acts as a collaborative platform for global deaths, including community mortality studies described in this supplement. We aimed to compare the age distribution of infant deaths <6 months occurring in the community with in-hospital. Results We studied 829 RSV-related deaths <1 year of age from 38 developing countries, including 166 community deaths from 12 countries. There were 629 deaths that occurred <6 months, of which 156 (25%) occurred in the community. Among infants who died before 6 months of age, median age at death in the community (1.5 months; IQR: 0.8−3.3) was lower than in-hospital (2.4 months; IQR: 1.5−4.0; P < .0001). The proportion of neonatal deaths was higher in the community (29%, 46/156) than in-hospital (12%, 57/473, P < 0.0001). Conclusions We observed that children in the community die at a younger age. We expect that maternal vaccination or immunoprophylaxis against RSV will have a larger impact on RSV-related mortality in the community than in-hospital. This case series of RSV-related community deaths, made possible through global data sharing, allowed us to assess the potential impact of future RSV vaccines

    Pertussis surveillance in a children hospital in Bangkok, Thailand

    No full text
    Objectives: To investigate the incidence, clinical characteristics and cost associated with pertussis in Thai children with persistent cough. Methods: A prospective study was conducted among children aged 0–18 years with persistent cough for ≥7 days with at least one of the following: paroxysm, inspiratory whooping, or post-tussive emesis. Nasopharyngeal swabs were obtained and tested for pertussis real time polymerase chain reaction (RT-PCR). Results: 19.6% of children (28 out of 143) had pertussis confirmed by RT-PCR, 75% of cases occurred in children who were too young to complete their primary series of vaccine. Paroxysm and post-tussive emesis were the most consistent clinical features, identified in 96% and 93% of cases, respectively, whooping was found in only 18%. Pertussis cases were more likely to have household cough contact (64% versus 30%, p < 0.001), be hospitalized (79% versus 58%, p = 0.048) and experience protracted duration of cough (47 vs. 20 days, p < 0.001) compare to their counterpart. Conclusion: Pertussis in Thai children is not infrequent and the common age group is young infant before completion of primary series of pertussis vaccine at six months of age, underline the importance of maternal pertussis immunization. Keyword: Pertussis, Thailand, Children, Whole-cell pertussis vaccine, Maternal immunizatio

    Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases

    No full text
    Adolescents with underlying diseases are at risk of severe COVID-19. The immune response of BNT162b2 may be poor among immunocompromised adolescents. We aim to describe immunogenicity of mRNA BNT162b2 among adolescents who are immunocompromised or have chronic diseases. We recruited adolescents 12&ndash;18 years of age; group A impaired-immunity (post-transplantation, cancer, on immunosuppressive drugs) and group B chronic diseases. A two-dose regimen of BNT162b2 was given. Immunogenicity was determined by surrogate virus neutralization test (sVNT) and IgG against receptor-binding domain (RBD). From August to October 2021, 312 adolescents, with a median age (IQR) of 15 years (13.7&ndash;16.5), were enrolled (group A 100, group B 212). The geometric means (GMs) of sVNT (% inhibition) against Delta strain and anti-RBD IgG (BAU/mL) after the 2nd dose among group A were: post-transplantation recipients 52.9 (95% CI 37.7&ndash;74.2) and 233.6 (95% CI 79&ndash;690.6); adolescents with cancer 62.3 (95% CI 29.2&ndash;133.1) and 214.9(95% CI 34.2&ndash;1348.6); and adolescents with other immunosuppressive conditions 66.7 (95% CI 52.4&ndash;84.8) and 849.8 (95% CI 393.4&ndash;1835.8). In group B were: adolescents living with HIV 98 (95% CI 97.3&ndash;98.8) and 3240.3 (95% CI 2699&ndash;3890.2), and adolescents with other chronic disease 98.6 (95% CI 98.3&ndash;98.9) and 3818.5 (95% CI 3490.4&ndash;4177.4). At day 90, immunity declined; among impaired-immunity participants were 43.9 (95% CI 30.8&ndash;62.4) and 178.7 (95% CI 91.2&ndash;350.1) and adolescents with chronic diseases were 90.6 (95% CI 88.4&ndash;92.8) and 1037.1 (95% CI 933.3&ndash;1152.5). In conclusion, adolescents with impaired immunity had a poor response to 2-doses of BNT162b2, additional dose should be considered. Adolescents with chronic diseases had excellent response but immunity waned after 3 m, booster dose may be required

    Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015

    No full text
    Abstract Background Thailand recommends influenza vaccination among pregnant women. We conducted a cohort study to determine if the prevalence of adverse events following immunization (AEFIs) with influenza vaccine among Thai pregnant women was similar to that often cited among healthy adults. Methods Women who were ≥17 gestational weeks and ≥18 years of age were recruited. Demographic and health history data were collected using structured questionnaires. Women were provided with symptom diary, ruler to measure local reaction(s), and thermometer to measure body temperature. AEFIs were defined as any new symptom/abnormality occurring within four weeks after vaccination. The diaries were abstracted for frequency, duration, and level of discomfort/inconvenience of the AEFIs. Serious adverse events (SAEs) and the likelihood of AEFIs being associated with vaccination were determined using standard definitions. Results Among 305 women enrolled between July–November 2015, median age was 29 years. Of these, 223 (73%) were in their third trimester, 271 (89%) had completed secondary school or higher, and 20 (7%) reported ≥1 pre-existing conditions. AEFIs were reported in 134 women (44%; 95% confidence interval [CI] 38–50%). Soreness at the injection site (74, 24%; CI 19–29%), general weakness (50, 16%; CI 12–21%), muscle ache (49, 16%; CI 12–21%), and headache (45, 15%; CI 1–19%) were most common. Of those with AEFIs, 120 (89%) reported symptom/abnormality occurred on day 0 or day 1 following vaccination. Ten women (7%) reported the AEFIs affected daily activities. The AEFIs generally spontaneously resolved within 24 h of onset. There were two vaccine-unrelated SAEs. Of 294 women with complete follow-up, 279 (95%) had term deliveries, 12 (4%) had preterm deliveries, and 3 (1%) had miscarriage or stillbirth. Conclusion In our cohort, AEFIs with influenza vaccine occurred with similar frequency to those reported among healthy adults in other studies, and were generally mild and self-limited. No influenza vaccine-associated SAEs were identified

    Standardization and evaluation of an Anti-ZIKV IgM ELISA assay for the serological diagnosis of zika virus infection

    No full text
    Here, we describe the development of the in-house anti-Zika virus (ZIKV) IgM antibody capture ELISA (in-house ZIKV IgM ELISA) for the detection and diagnosis of acute ZIKV infections. We compared the in-house ZIKV IgM ELISA assay performance against two commercial kits, Euroimmun ZIKV IgM and InBios 2.0 ZIKV IgM ELISA. We tested the assays\u27 ability to detect anti-ZIKV IgM using a well-defined serum sample panel. This panel included 80 ZIKV negative samples (20 negative, 20 found to be primary dengue virus [DENV][ infections, 20 secondary DENV infections, and 20 Japanese encephalitis virus [JEV] infections) and 67 ZIKV reverse transcriptase-polymerase chain reaction-positive acute serum samples. The OD values were calculated to enzyme immunoassay (EIA) unts by comparing them to weak positive controls. The results demonstrated the high sensitivity (88.06%) and specificity (90.00%) of our in-house ZIKV IgM ELISA and its 89.12% overall percentage agreement. The kappa values were deemed to be within excellent range and comparable to the InBios ZIKV IgM ELISA. Some cross-reactivity was observed among secondary DENV and JEV samples, and to a much lower extent, among primary DENV samples. These data indicate that our in-house ZIKV IgM ELISA is a reliable assay for the detection of anti-ZIKV IgM antibodies in serum
    • …
    corecore